Research programme: pegylated GM-CSF - CangeneAlternative Names: Research programme: PEG granulocyte macrophage colony-stimulating factor - Cangene; Research programme: PEG-GM-CSF - Cangene
Latest Information Update: 28 Feb 2014
At a glance
- Originator Cangene Corporation
- Mechanism of Action Granulocyte macrophage colony stimulating factor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neutropenia